Abstract
Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the succe......
小提示:本篇文献需要登录阅读全文,点击跳转登录